Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial

Abstract Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the eff...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yehudit Bloch, R. H. Belmaker, Pesach Shvartzman, Pnina Romem, Arkady Bolotin, Yuly Bersudsky, Abed N. Azab
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0164be22763d4d4cbf2b01982a8dbe38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0164be22763d4d4cbf2b01982a8dbe38
record_format	dspace
spelling	oai:doaj.org-article:0164be22763d4d4cbf2b01982a8dbe382021-12-02T17:26:49ZNormobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial10.1038/s41598-021-98245-92045-2322https://doaj.org/article/0164be22763d4d4cbf2b01982a8dbe382021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98245-9https://doaj.org/toc/2045-2322Abstract Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18–65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were − 4.2 ± 0.3 points in the oxygen-treated group and − 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] − 5.95 to − 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI − 1.00 to − 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression. Trial registration: NCT02149563 (29/05/2014).Yehudit BlochR. H. BelmakerPesach ShvartzmanPnina RomemArkady BolotinYuly BersudskyAbed N. AzabNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yehudit Bloch R. H. Belmaker Pesach Shvartzman Pnina Romem Arkady Bolotin Yuly Bersudsky Abed N. Azab Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
description	Abstract Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18–65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were − 4.2 ± 0.3 points in the oxygen-treated group and − 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] − 5.95 to − 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI − 1.00 to − 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression. Trial registration: NCT02149563 (29/05/2014).
format	article
author	Yehudit Bloch R. H. Belmaker Pesach Shvartzman Pnina Romem Arkady Bolotin Yuly Bersudsky Abed N. Azab
author_facet	Yehudit Bloch R. H. Belmaker Pesach Shvartzman Pnina Romem Arkady Bolotin Yuly Bersudsky Abed N. Azab
author_sort	Yehudit Bloch
title	Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_short	Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_full	Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_fullStr	Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_full_unstemmed	Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_sort	normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0164be22763d4d4cbf2b01982a8dbe38
work_keys_str_mv	AT yehuditbloch normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT rhbelmaker normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT pesachshvartzman normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT pninaromem normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT arkadybolotin normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT yulybersudsky normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial AT abednazab normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
_version_	1718380770838446080

Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial

Ejemplares similares